NOT FOR DISTRIBUTION
Header cover image

Market Cap

HK$13.3b

Last Updated

2021/04/11 10:18 UTC

Data Sources

Company Financials +

Executive Summary

Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Ocumension Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1477 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 1477's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-6.9%

1477

0.8%

HK Pharmaceuticals

-1.1%

HK Market


1 Year Return

n/a

1477

21.2%

HK Pharmaceuticals

28.6%

HK Market

Return vs Industry: Insufficient data to determine how 1477 performed against the Hong Kong Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 1477 performed against the Hong Kong Market.


Shareholder returns

1477IndustryMarket
7 Day-6.9%0.8%-1.1%
30 Day-5.5%0.7%-1.8%
90 Day-27.4%10.0%3.4%
1 Yearn/a23.0%21.2%33.5%28.6%
3 Yearn/a-14.3%-19.1%4.0%-6.9%
5 Yearn/a79.2%62.4%48.7%23.7%

Long-Term Price Volatility Vs. Market

How volatile is Ocumension Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ocumension Therapeutics undervalued compared to its fair value and its price relative to the market?

4.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1477's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1477's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1477 is unprofitable, so we can't compare its PE Ratio to the HK Pharmaceuticals industry average.

PE vs Market: 1477 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1477's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1477 is overvalued based on its PB Ratio (4.3x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is Ocumension Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

84.3%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1477's forecast earnings growth is above the savings rate (1.5%).

Earnings vs Market: Insufficient data to determine if 1477's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1477's revenue (84.3% per year) is forecast to grow faster than the Hong Kong market (13.3% per year).

High Growth Revenue: 1477's revenue (84.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1477 is forecast to be unprofitable in 3 years.


Past Performance

How has Ocumension Therapeutics performed over the past 5 years?

-71.5%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 1477 is currently unprofitable.

Growing Profit Margin: 1477 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 1477's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 1477's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1477 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).


Return on Equity

High ROE: 1477 has a negative Return on Equity (-90.51%), as it is currently unprofitable.


Financial Health

How is Ocumension Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 1477's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥91.9M).

Long Term Liabilities: 1477's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥5.3M).


Debt to Equity History and Analysis

Debt Level: 1477 is debt free.

Reducing Debt: 1477 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 1477 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 1477 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Ocumension Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1477's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1477's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1477's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1477's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1477's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Victor Liu (47 yo)

2.67yrs

Tenure

Mr. Ye Liu, also known as Victor, serves as Chief Executive Officer at Ocumension Therapeutics since joining on August 1, 2018 and has been its Executive Director since November 23, 2018. Mr. Liu is respon...


Leadership Team

Experienced Management: 1477's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: 1477's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: 1477 only recently listed within the past 12 months.


Top Shareholders

Company Information

Ocumension Therapeutics's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ocumension Therapeutics
  • Ticker: 1477
  • Exchange: SEHK
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$13.342b
  • Shares outstanding: 619.14m
  • Website: https://www.ocumension.com

Number of Employees


Location

  • Ocumension Therapeutics
  • No. 1858 Yinzhongnan Road
  • Guoxiang Subdistrict
  • Suzhou
  • Jiangsu Province
  • China

Listings


Biography

Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company researches and develops, manufactures, and commercializes ophthalmic drugs. ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 10:18
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.